



REMARKS

1. Applicants hereby submit the following:
 - [XX] a paper copy of a "Sequence Listing", complying with §1.821(c), to be incorporated into the specification as directed above;
 - [] an amendment to the paper copy of the "Sequence Listing" submitted on , the amendment being in the form of substitute sheets;
 - [XX] the Sequence Listing in computer readable form, complying with §1.821(e) and §1.824, including, if an amendment to the paper copy is submitted, all previously submitted data with the amendment incorporated therein;
 - [] pursuant to §1.821(e), reference is made to the computer readable form filed on , in USSN , which presents the identical Sequence information, the use of which is now requested, in lieu of submitting a new computer readable form; and/or
 - [] a substitute computer readable form to replace one found to be damaged or unreadable.

[XX] 2. The description has been amended to comply with §1.821(d).

3. The undersigned attorney or agent hereby states as follows:

- (a) this submission is not believed to include new matter [§1.821(g)];
- (b) the contents of the paper copy (as amended, if applicable) and the computer readable form of the Sequence Listing, are believed to be the same [§1.821(f) and §1.825(b)];
- (c) if the paper copy has been amended, the amendment is believed to be supported by the specification and is not believed to include new matter [§1.825(a)]; and
- (d) if the computer readable form submitted herewith is a substitute for a form found upon receipt by the PTO to be damaged or unreadable, that the substitute data is believed to be identical to that originally filed [§1.825(d)].

4. Under U.S. rules, each sequence must be classified in <213> as an "Artificial Sequence", a sequence of "Unknown" origin, or a sequence originating in a particular organism, identified by its scientific name.

Neither the rules nor the MPEP clarify the nature of the relationship which must exist between a listed sequence and an organism for that organism to be identified as the origin of the sequence under <213>.

Hence, counsel may choose to identify a listed sequence as associated with a particular organism even though that sequence does not occur in nature by itself in that organism (it may be, e.g., an epitopic fragment of a naturally

occurring protein, or a cDNA of a naturally occurring mRNA, or even a substitution mutant of a naturally occurring sequence). Hence, the identification of an organism in <213> should not be construed as an admission that the sequence *per se* occurs in nature in said organism.

Similarly, designation of a sequence as "artificial" should not be construed as a representation that the sequence has no association with any organism. For example, a primer or probe may be designated as "artificial" even though it is necessarily complementary to some target sequence, which may occur in nature. Or an "artificial" sequence may be a substitution mutant of a natural sequence, or a chimera of two or more natural sequences, or a cDNA (i.e., intron-free sequence) corresponding to an intron-containing gene, or otherwise a fragment of a natural sequence.


The Examiner should be able to judge the relationship of the enumerated sequences to natural sequences by giving full consideration to the specification, the art cited therein, any further art cited in an IDS, and the results of his or her sequence search against a database containing known natural sequences.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made".

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By


PETER P. COOPER
Registration No. 28,005

IPC:a1
624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
F:\,H\hoib\Moestrup1A\RESPONSE TO NOTICE TO COMPLY.doc



VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification:

The two paragraphs beginning at line 18 and ending at line 20 of page 4 have been amended as follows:

Fig. 4: shows 9 different haptoglobin sequences (SEQ ID_NOS:1-9)

Fig. 5: shows 4 different CD163 sequences (SEQ_ID_NOS:10-13)

The paragraph beginning at line 16 and ending at line 24 of page 7 has been amended as follows:

sp|P00737|HPT1_HUMAN (SEQ_ID_NO:1)

sp|P00738|HPT2_HUMAN (SEQ_ID_NO:2)

sp|P50417|HPT_ATEGE (SEQ_ID_NO:3)

tr|Q60574|Q60574 (SEQ_ID_NO:4)

tr|Q61646|Q61646 (SEQ_ID_NO:5)

sp|Q62558|HPT_MUSSA (SEQ_ID_NO:6)

sp|P06866|HPT_RAT (SEQ_ID_NO:7)

tr|O35086|O35086 (SEQ_ID_NO:8)

sp|P19006|HPT_CANFA (SEQ_ID_NO:9)

The paragraph beginning at line 34 of page 7 has been amended as follows:

VLSPADKTNVKAAGKVGAGAHAGEYGAEEALERMFLSFPTTKTYFPHFDSLH

GSAQVKHGKKVADALNTAVAHVDDMPNALSALSIDLHAKLRLVPVNFKL

LSHCLLVTAAHLPAEFTPAVHASLDKFLASVSTVLTSKYR (SEQ_ID_NO:14)

The paragraph beginning at line 4 of page 8 has been amended as follows:

VHLTPEEKSAVTALWGKVNDEVGGEALGRLLVVYPWTQRFFESFGDLST
PDAVMGNPKVKAHGKKVLGAFSDGLAHDNLKGTFATLSELHCDKLHVDP
ENFRLLGNVLVCVLAHHFGKEFTPQVAAYQKVVAGVANALAHKYH (SEQ_ID:15)

The paragraph beginning at line 11 of page 8 has been amended as follows:

VHLTPEEKTAVNALWGKVNDAVGGEALGRLLVVYPWTQRFFESFGDLSS
PDAVMGNPKVKAHGKKVLGAFSDGLAHDNLKGTFSQLSELHCDKLHVDP
ENFRLLGNVLVCVLAHNGKEFTPQMQAAYQKVVAGVANALAHKYH (SEQ_ID:16)

The paragraph beginning at line 19 of page 8 has been amended as follows:

GHFTEEDKATITS娄WGKVNVEDAGGETLGRLLVYPWTQRFFDSFGNLSS
ASAIMGNPKVKAHGKKVLTSGLDAIKHLDLKGTFAQLSELHCDKLHVDP
ENFKLLGNVLTVLAIHFGKEFTPQEVQASWQKMVTAVASALSSRYH (SEQ_ID:17)

The paragraph beginning at line 26 of page 8 has been amended as follows:

ALSAEDRALVRALWKLGNSNVGYTTEALERTFLAFTPATKTYFSHLDLSP
GSSQVRAHGQKVADALS LAVERLDDLPHALSALS HACQLRVDPASFQL
LGHCLLVTLARHYPGDFSPALQASLDKFLSHVISALVSEYR (SEQ_ID:18)

The paragraph beginning at line 33 of page 8 has been amended as follows:

SLTKTERTIIIVSMWA KISTQADTIGETLERLFLSHPQT KTYFPHF D LHP

GSAQLRAHGSKVVAVGDAVKSIDDIGGALSKLSELHAYILRVDPVNFKL
LSHCLLVTLAARFPADFTAEEAHAAWDKFLSVSSVLTEKYR (SEQ_ID_NO:19)

The paragraph beginning at line 1 of page 9 has been amended as follows:

VHFTAEEKAAVTSLWSKMNVVEAGGEALGRLLVVYPWTQRFFDSFGNLSS
PSAILGNPKVKAHGKKVLTSFGDAIKNMDNLKPAFAKLSELHCDKLHVDP
ENFKLLGNVMVIILATHFGKEFTPEVQAAWQKLVSABAIALAHKYH (SEQ_ID_NO:20)

The paragraph beginning at line 9 of page 9 has been amended as follows:

MVHLTPVEKSAVTAXWGKVNVDDEVGEALGRLLVVYPWTQRFFESFGDLS
TPDAVMGNPKVKAHGKKVLGAESDGLAHLNDLKGTFATLSELHCDKLHVDP
PENFRLLGNVLVCVLAAHFGKEFTPVQAAYQKVVAGVANALAHKYH (SEQ_ID_NO:21)

The paragraph beginning at line 19 of page 13 has been amended as follows:

In particular the fragments may comprise a sequence corresponding to aa 103-347 of sp|P00737 (SEQ_ID_NO:1) in Fig. 4 or to aa 162-406 of sp|P00738 (SEQ_ID_NO:2).

The paragraph beginning at line 30 and ending at line 33 of page 21 has been amended as follows:

tr|Q07898|Q07898 (SEQ_ID_NO:10)
tr|Q07901|Q07901 (SEQ_ID_NO:11)
tr|Q07900|Q07900 (SEQ_ID_NO:12)
tr|Q07899|Q07899 (SEQ_ID_NO:13)

The paragraph beginning at line 30 of page 25 has been amended as follows:

The domains are in one embodiment arranged as follows with respect to the CD163 sequence (SEQ_ID_NO:10):

The paragraph beginning at line 16 of page 40 has been amended as follows:

cDNA encoding SRCR domain 1-6 and SRCR domain 5-9 extended with Hind III and Xho I restriction sites were amplified by polymerase chain reactions (PCR) using full-length HbSR cDNA (Kristiansen,M., Graversen,J.H., Jacobsen,C., Sonne,O., Hoffman,H., Law,A.S.K., and K.,M.S.K. (2001) Identification of the hemoglobin scavenger receptor, *Nature* 409, 198-201) as template. The PCR products were subcloned into the expression vector pSecTag2B (Invitrogen, Groningen, The Netherlands) by use of the restriction sites HindIII and XhoI. Plasmids were transformed into *E. coli* DH5 α cells (Clontech, Palo Alto, CA, USA), and plasmid DNA isolated and sequenced prior to transfection. The following primers were used for construction of the fragments: SRCR domain 1-6: forward 5'-caagcttggAACAGACAAGGAGCTG-3' (SEQ_ID_NO:22) and reverse 5'-cctcgAGTCTGAGCAGATTACAGAG-3' (SEQ_ID_NO:23). SRCR domain 5-9: forward 5'-caagcttcACAGGGAAcccAGACTG-3' (SEQ_ID_NO:24) and reverse 5'-cctcgAGATCTGTGCAATTACTGC-3' (SEQ_ID_NO:25).